[Combined GnRH analogs/hMG/hCG treatment].
Ovarian stimulation with human menopausal gonadotropins after Gn-RH-analogue induced pituitary desensitization has been shown to optimize the follicular maturation. This is mostly due to the avoidance of irregular endogenous LG-reactions which occur during hMG-therapy in about one third of the treatment cycles. In several studies using Buserelin or Decapeptyl as Gn-RH-analogue 282 patients were treated for in vitro fertilization, gamete intrafallopian transfer or as part of an "in vivo" therapy. Pregnancy rates were significantly improved in all groups: HMG/hCG therapy resulted in a pregnancy rate of 17% per patient whereas by the combined therapy in 25% of the patients a pregnancy was achieved.
Braendle
W
W
Abteilung für klinische und experimentelle Endokrinologie, Universitätskrankenhaus-Eppendorf.
D002064:Buserelin / Q000008:administration & dosage*; D006063:Chorionic Gonadotropin / Q000008:administration & dosage*; D003131:Combined Modality Therapy; D004624:Embryo Transfer / Q000379:methods*; D005260:Female; D005307:Fertilization in Vitro / Q000379:methods*; D015181:Gamete Intrafallopian Transfer / Q000379:methods*; D007987:Gonadotropin-Releasing Hormone / Q000008:administration & dosage; D006801:Humans; D008596:Menotropins / Q000008:administration & dosage*; D010062:Ovulation Induction / Q000379:methods*; D017329:Triptorelin Pamoate
D006063:Chorionic Gonadotropin; D017329:Triptorelin Pamoate; D007987:Gonadotropin-Releasing Hormone; D008596:Menotropins; D002064:Buserelin
Kombinierte Gn-RH-Analogen/hMG/hCG-Behandlung.